CT-868

Q: What did studies of CT-868 find?

Studies of CT-868 measured 2 outcomes; the most studied are body weight (1 study) and HbA1c (1).

CT-868 has been studied in 2 papers since 2021: 1 trial in people, 1 review; 1 in the past year. The newest story, Oct 28, 2026: “Blood sugar fell in adults with type 1 diabetes and excess weight”.

Intervention

2 papers study it2 findingsUpdated Oct 28, 2026

More peptides

1 new paper in 30 daysSee all 2

“nominally significant placebo-adjusted difference for 4.1 mg: -0.3% [90% CI -0.6 to -0.1]; P = 0.020”

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or ObesityDiabetes care2026doi:10.2337/dc26-1059

None of its findings points the other way.

1 lab
1 trial, none about aging

Funder: Carmot Therapeutics
2 of 2 findings with company ties
1 of 1 trial sponsored by its developers

Human trial1

Studies in people

1 study gave CT-868 to people and measured what changed.

down: Decreases HbA1cPlacebo-adjusted difference -0.3 percentage points (90% CI -0.6 to -0.1); P = 0.020
down: Decreases body weightLS mean change -3.3 to -6.7% versus 0.3% with placebo; all P < 0.01
Randomized trial111 peopleadults16 weeks
Type 1 diabetes and overweight or obesity
Diabetes care, Oct 28, 2026

What did studies of CT-868 find?

Studies of CT-868 measured 2 outcomes; the most studied are body weight (1 study) and HbA1c (1).

Body weight

downin humans1

1 study

CT-868 decreases body weight in humans (type 1 diabetes and overweight or obesity; compared with placebo) (LS mean change -3.3 to -6.7% versus 0.3% with placebo; all P < 0.01).
“Acmopatide-treated participants demonstrated reductions in body weight (LS mean CFB -3.3 to -6.7% vs. 0.3% with placebo; all P < 0.01)”
Human trialtype 1 diabetes and overweight or obesity; compared with placebo1.8, 4.1, or 6.6 mg once daily16 weeks
Blood sugar fell in adults with type 1 diabetes and excess weight
Diabetes careOct 28, 2026

HbA1c

downin humans1

1 study

CT-868 decreases HbA1c in humans (type 1 diabetes and overweight or obesity; compared with placebo) (Placebo-adjusted difference -0.3 percentage points (90% CI -0.6 to -0.1); P = 0.020).
“nominally significant placebo-adjusted difference for 4.1 mg: -0.3% [90% CI -0.6 to -0.1]; P = 0.020”
Human trialtype 1 diabetes and overweight or obesity; compared with placebo4.1 mg once daily16 weeks
Blood sugar fell in adults with type 1 diabetes and excess weight
Diabetes careOct 28, 2026

Who is developing CT-868?

1 company: Carmot Therapeutics.

Companies: Carmot TherapeuticsPhase 2overweight, obese

Trial sponsors

Carmot Therapeutics
Company1 trialPhase 2111 people

Latest

1 paper in 12 months

Diabetes CareOct 28

Blood sugar fell in adults with type 1 diabetes and excess weight

A measure of longer-term blood sugar fell 0.4 to 0.6 percentage points with acmopatide versus 0.3 points with placebo over 16 weeks.A measure of longer-term blood sugar fell 0.4 to 0.6 percentage points with acmopatide versus 0.3 points with placebo over 16 weeks.

Randomized trial · 111 peopleType 1 diabetes